Brief: Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts
15/05/2025 12:34
May 15 (Reuters) - Cabaletta Bio Inc CABA.O: CABALETTA BIO ANNOUNCES 2027 RESE-CEL BLA SUBMISSION ANTICIPATED IN MYOSITIS FOLLOWING RECENT FDA ALIGNMENT ON REGISTRATIONAL COHORTS CABALETTA BIO INC: SLE AND LN REGISTRATIONAL DISCUSSIONS WITH FDA ANTICIPATED IN 3Q25 CABALETTA BIO INC: SYSTEMIC SCLEROSIS REGISTRATIONAL DISCUSSIONS WITH FDA ANTICIPATED IN 4Q25 Source text: ID:nGNX2zGZHw Further company coverage: CABA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview